AZD6765

Lanicemine

Lanicemine

Chemical compound

Lanicemine (AZD6765) is a low-trapping NMDA receptor antagonist that was under development by AstraZeneca for the management of severe and treatment-resistant depression.[1][2] Lanicemine differs from ketamine in that it is a low-trapping NMDA receptor antagonist, showing similar rapid-acting antidepressant effects to ketamine in clinical trials but with little or no psychotomimetic side effects.[3] However, lanicemine did not meet study endpoints, and its development was terminated by AstraZeneca in 2013.[4]

Quick Facts Clinical data, ATC code ...

See also

References

  1. [1]
    "Lanicemine". AdisInsight. Retrieved 18 June 2017.
  2. [2]
    Machado-Vieira R, Henter ID, Zarate CA (May 2017). "New targets for rapid antidepressant action". Progress in Neurobiology. 152: 21–37. doi:10.1016/j.pneurobio.2015.12.001. PMC 4919246. PMID 26724279.
  3. [3]
    Zarate CA, Mathews D, Ibrahim L, Chaves JF, Marquardt C, Ukoh I, et al. (August 2013). "A randomized trial of a low-trapping nonselective N-methyl-D-aspartate channel blocker in major depression". Biological Psychiatry. 74 (4): 257–64. doi:10.1016/j.biopsych.2012.10.019. PMC 3594049. PMID 23206319.
  4. [4]
    Flowers S. "Return to growth: AstraZeneca's CEO Pascal Soriot says 2013 was year of "momentum" for the company". Retrieved 6 February 2014.
Share this article:

This article uses material from the Wikipedia article AZD6765, and is written by contributors. Text is available under a CC BY-SA 4.0 International License; additional terms may apply. Images, videos and audio are available under their respective licenses.